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RESEARCH ARTICLE Open Access
Gender differences in attitudes impeding
colorectal cancer screening
Paul Ritvo1,2*, Ronald E Myers3, Lawrence Paszat4,5, Mardie Serenity6, Daniel F Perez1,2 and Linda Rabeneck7,8
Abstract
Background: Colorectal cancer screening (CRCS) is the only type of cancer screening where both genders reduce
risks by similar proportions with identical procedures. It is an important context for examining gender differences in
disease-prevention, as CRCS significantly reduces mortality via early detection and prevention. In efforts to increase
screening adherence, there is increasing acknowledgment that obstructive attitudes prevent CRCS uptake. Precise
identification of the gender differences in obstructive attitudes is necessary to improve uptake promotion. This
study randomly sampled unscreened, screening - eligible individuals in Ontario, employing semi-structured
interviews to elicit key differences in attitudinal obstructions towards colorectal cancer screening with the aim of
deriving informative differences useful in planning promotions of screening uptake.
Methods: N = 81 participants (49 females, 32 males), 50 years and above, with no prior CRCS, were contacted via
random-digit telephone dialing, and consented via phone-mail contact. Altogether, N = 4,459 calls were made to
yield N = 85 participants (1.9% response rate) of which N = 4 participants did not complete interviews. All subjects
were eligible for free-of-charge CRCS in Ontario, and each was classified, via standard interview by CRCS screening
decision-stage. Telephone-based, semi-structured interviews (SSIs) were employed to investigate gender differences
in CRCS attitudes, using questions focused on 5 attitudinal domains: 1) Screening experience at the time of
interview; 2) Barriers to adherence; 3) Predictors of Adherence; 4) Pain-anxiety experiences related to CRCS; 5)
Gender-specific experiences re: CRCS, addressing all three modalities accessible through Ontario’s program: a) fecal
occult blood testing; b) flexible sigmoidoscopy; c) colonoscopy.
Results: Interview transcript analyses indicated divergent themes related to CRCS for each gender: 1) bodily
intrusion, 2) perforation anxiety, and 3) embarrassment for females and; 1) avoidant procrastination with underlying
fatalism, 2) unnecessary health care and 3) uncomfortable vulnerability for males. Respondents adopted similar
attitudes towards fecal occult blood testing, flexible sigmoidoscopy and colonoscopy, and were comparable in
decision stage across tests. Gender differences were neither closely tied to screening stage nor modality. Women
had more consistent physician relationships, were more screening-knowledgeable and better able to articulate
views on screening. Men reported less consistent physician relationships, were less knowledgeable and kept
decision-making processes vague and emotionally distanced (i.e. at ‘arm’s length’).
Conclusions: Marked differences were observed in obstructive CRCS attitudes per gender. Females articulated
reservations about CRCS-associated distress and males suppressed negative views while ambiguously
procrastinating about the task of completing screening. Future interventions could seek to reduce CRCS-related
stress (females) and address the need to overcome procrastination (males).
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Background
Colorectal cancer screening (CRCS) is the only type of can-
cer screening where both genders receive identical
procedures and confront comparable risks reduced by
similar proportions. CRCS is an important context for
examining male–female differences in disease-preventive
behaviour, because it significantly reduces mortality via
early detection (greater likelihood of effective, curative
treatment) and prevention (colonoscopy-detected polyps
are removable before they become malignant tumours) [1].
Because increased CRCS uptake rates are statistically pro-
portional to reduced mortality [2-7], international efforts
are aimed at increasing CRCS rates (e.g. in Canada, United
States, Australia, United Kingdom, France, Israel, India,
and Italy). Amidst the continual search for approaches that
increase uptake, there is acknowledgment that obstructive
attitudes impede CRCS [8-13]. Accordingly, precisely iden-
tifying screening-obstructive attitudes is necessary for de-
vising interventions to overcome them.
Existing data suggest the obstructive attitudes that stop
or delay CRCS and other preventive health behaviours
differ by gender [9,14-21]. Accordingly, identification of
gender-specific obstructions can be used to more precisely
target and resolve the cognitions that impede use of life-
improving, life-saving procedures. In addressing how
males and females approach CRCS differently, the basic
findings of poorer male health (than females), reflected in
higher mortality rates [22,23] and the identification of
male gender as a significant mortality risk are linked to
the less frequent use of health services [24-27]. Even when
males progress to health care contacts, they unfortunately
spend less time during doctor visits than women, receiving
less advice about risk factor reduction [24,27-30]. Male–
female CRCS comparisons can help shed light on these
deficits in male health care help-seeking given the greater
acceptance of and use of health care services by women,
and higher screening levels across female socioeconomic-
ethnic groups [31,32]. The factors described above likely
contributed to a recent finding in a population-based
study of CRCS in 1013 adults (aged 50 years and above)
where a larger proportion of males (55%) than females
(46%) had never heard of Fecal Occult Blood Testing
(FOBT), the typical entry-level CRCS modality [33,34].
Female-specific CRCS research, on the other hand, indi-
cates aversion (when compared to men) to both endoscopic
screening (internal scoping in flexible sigmoidoscopy or
colonoscopy) and FOBT (fecal sampling) [35-45]. In the
same population-based study cited above, of the individuals
reporting FOBTawareness, 26% of females vs. 17% of males
were not considering obtaining FOBT screening [33]. This
pattern of greater female FOBT rejection was also found in
a patient sample of primary care practice attendees in the
US, by Myers et al. [46]. Other findings, however, have
identified advantages for males. For example, more men
than women attended screening (73% versus 67%) in a large
UK community trial of Flexible Sigmoidoscopy (N = 5462)
although the higher male attendance was partially explained
by the lower levels of socioeconomic deprivation, higher
levels of marital status and lower perceived screening
barriers in male study participants [16]. Male gender was
found to be a significant positive factor for screening uptake
(CRC) in accordance with guideline recommendations in
an Australian study within a population-based sample of
First Degree Relatives (FDRs) of CRC-diagnosed indi-
viduals [47]. These male-advantage findings, however, are
countered by results from a review of intervention studies
meeting moderate methodological rigour where two trials
with gender-based analyses demonstrated better effects in
females than males [48-50], while in five other trials, no
gender-based differences were found [51-55]. Another
review focused specifically on participation equity in colo-
rectal cancer screening amongst population subgroups:
eight studies were identified that explored gender inequity
in access/utilization of CRC screening, and in six of these
a higher rate of screening participation was found amongst
women compared to men, although screening test type,
participant type (membership in high versus low risk
groups), and age were found to interact with gender [56].
Two studies demonstrated partial results in that women
were more likely to undertake FOBT but less likely to
undertake invasive endoscopy or colonoscopy than males
[57,58]. In still another review of studies [59] aimed at
ascertaining CRC screening rates and impacting factors,
10 randomized trials [60-69] and seven non-randomized
studies [70-76] were identified with FOBT screening out-
comes while 8 studies were identified with sigmoidoscopy
[69,71,76-81] and 2 with colonoscopy outcomes [79,82];
no systematic male–female differences emerged from
these studies [59]. Altogether, while there seems a female
advantage to some degree, the varying results suggest a
need to better understand attitudinal obstacles for both
sexes in the detailed descriptions that can be derived from
qualitative findings.
Because better understandings of male–female reactions
to CRCS can be useful in increasing uptake and informing
other health promotion efforts, we undertook a qualitative,
interview-based study to pinpoint gender-specific obstruct-
ive attitudes. Having directly completed survey studies on
gender-related CRCS differences [33,34], we opted for
qualitative study to more thoroughly investigate differences
via semi-structured interviews, using a population-based
recruitment. The transcribed interviews were analyzed to
focally identify attitudinal obstructions related to three
standard screening modalities (FOBT, Flexible Sigmoidos-
copy, Colonoscopy) with the intent of deriving data useful
in specifically tailoring CRCS promotions to each gender.
As this study was undertaken in Canada, it is important to
note that the Canadian Association of Gastroenterology
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recommended in a 2010 update [83] of their 2004 screen-
ing recommendations [84] that individuals of average risk
participate in one or both of the following screening
regimes: 1) FOBT every 1–2 years or 2) Flexible Sigmoidos-
copy every 10 years or longer, with colonoscopy used when
judged necessary. Recommendations for screening vary by
region and are continuously reviewed, but generally follow
a similar approach to Cancer Care Ontario’s Colon Cancer
Check, (used here as an example) that individuals 50–75
years of age perform an FOBT every 1–2 years or receive a
colonoscopy approximately every five to ten years depen-
ding on baseline risk.
Methods
Telephone-based, semi-structured interviews (SSIs) were
undertaken by trained interviewers to explore gender
differences in attitudes towards CRCS. The SSI ques-
tions addressed three screening modalities accessible
free-of-charge through Ontario’s screening program: a)
FOBT; b) Flexible sigmoidoscopy; and c) Colonoscopy,
and focused on 5 attitudinal domains selected to reflect
attitudes that would obstruct or facilitate screening up-
take, accenting frequently-cited obstructive perceptions
(e.g. pain and anxiety) and conscious gender differences
(and those the subject was not consciously aware of ).
1) Screening Experience at the Time of Interview
2) Key Barriers to CRC Screening Adherence
3) Key Factors Predicting CRC Screening Adherence
4) Experience of Pain and Anxiety Reponses related to
CRC Screening
5) Experience of Gender – Differences in CRC
Screening
Standard descriptions and explanations of screening
modalities were provided when participants indicated
knowledge deficits, following the goal of helping par-
ticipants respond from informed perspectives (based
on their personal view of necessary information). This
supplementation of current knowledge was carefully
undertaken to avoid communicating biases favouring
specific attitudes. (See Table 1 for Semi-structured
interview schedule).
Participants were males and females, 50 years and
above, with no prior history of CRC screening, initially
contacted by random-digit-dialing who consented to
study participation by phone and mail contacts. All were
eligible for free-of-charge CRC screening in Ontario and
each subject was assessed, using a standard interview,
for CRCS screening decision stage using the following
criteria: Stage 1 (never heard of the screening modality);
Stage 2 (aware but not currently considering screening);
Stage 3 (aware, decided against screening); Stage 4
(aware, undecided); and Stage 5 (decided to undergo
Table 1 Semi-structured interview schedule
Patient’s current experience of CRC screening - FOBT
What are your current feelings
about FOBT screening for colon
cancer?
What do you know about FOBT
screening and what do you feel
are the most important points to
know about?
What do you feel are the Pros and
Cons of FOBT screening?
What do you feel are the
important male – female
differences in FOBT screening?
What do you see as the
advantages of getting FOBT
screening over not getting FOBT
screening?
How do you feel you approach
FOBT screening differently than a
(male, female – whichever is the
opposite sex)?
What do you see as the advantages
of not getting FOBT screening over
getting FOBT screening?
What do you feel are important
points about FOBT screening that
we may not have yet covered?
Patient’s current experience of CRC screening - flexible sigmoidoscopy
What are your current feelings
about Flexible Sigmoidoscopy (FS)
screening for colon cancer?
What do you know about FS
screening and what do you feel
are the most important points to
know about?
What do you feel are the Pros and
Cons of FS screening?
What do you feel are the
important male – female
differences in FS screening?
What do you see as the
advantages of getting screened
with FS screening over not getting
screened with FS screening?
How do you feel you approach FS
screening differently than a (male,
female – whichever is identified as
the opposite sex)?
What do you see as the advantages
of not getting screened with FS
screening over getting screened
with FS screening?
What do you feel are important
points about FS screening that we
may not have yet covered?
Patient’s current experience of CRC screening - colonoscopy
What are your current feelings
about Colonoscopy screening for
colon cancer?
What do you know about
Colonoscopy screening and what
do you feel are the most
important points to know about?
What do you feel are the Pros and
Cons of Colonoscopy screening?
What do you feel are the
important male – female
differences in Colonoscopy
screening? How do you feel you
approach Colonoscopy screening
differently than a (male, female –
whichever is identified as the
opposite sex)?
What do you see as the
advantages of getting screened
with Colonoscopy screening over
not getting screened with
Colonoscopy screening?
What do you feel are important
points about Colonoscopy
screening that we may not have
yet covered?
What do you see as the
advantages of not getting
screened with Colonoscopy
screening over getting screened
with Colonoscopy screening?
Patient’s experience of key barriers to CRC screening adherence
What do you see as the major
barriers for you in approaching
FOBT screening?
What do you see as the major
barriers for you, if you choose to
obtain Flexible Sigmoidoscopy
screening, in sustaining annual or
biennial Flexible Sigmoidoscopy
screening?
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Table 1 Semi-structured interview schedule (Continued)
What do you see as the major
barriers for you in obtaining
enough knowledge about FOBT?
What do you feel are important
points about major barriers in
approaching Flexible
Sigmoidoscopy that we may not
have yet covered?
What do you see as the major
barriers for you, if you choose to
obtain FOBT screening, in sustaining
annual or biennial FOBT screening?
What do you see as the major
barriers for you in approaching
Colonoscopy?
What do you feel are important
points about major barriers in
approaching FOBT that we may
not have yet covered?
What do you see as the major
barriers for you in obtaining
enough knowledge about
Colonoscopy?
What do you see as the major
barriers for you in approaching
Flexible Sigmoidoscopy?
What do you see as the major
barriers for you, if you choose to
obtain Colonoscopy screening, in
sustaining annual or biennial
Colonoscopy screening?
What do you see as the major
barriers for you in obtaining
enough knowledge about Flexible
Sigmoidoscopy?
What do you feel are important
points about major barriers in
approaching Colonoscopy that we
may not have yet covered?
Patient’s experience of key factors predicting CRC screening adherence
What do you think and feel about
the ‘effectiveness’ of FOBT? How
well do you feel FOBT screening
can accurately tell whether you or
anyone else has colorectal cancer ?
What do you think and feel about
how susceptible you feel you are to
‘getting’ colorectal cancer? In other
words, how likely do you feel you
are to get colorectal cancer in your
lifetime? Why do you feel you are as
susceptible to colorectal cancer as
you have indicated you are?
What do you think and feel about
the ‘effectiveness’ of Flexible
Sigmoidoscopy? How well do you
feel Flexible Sigmoidoscopy
screening can accurately tell
whether you or anyone else has
colorectal cancer ?
Who do you feel influences you in
terms of colorectal cancer
screening? Can you talk about the
influences of your family doctor,
your spouse and/or members of
your family? How active are these
people in supporting you in
obtaining colorectal screening? Do
they ever oppose your getting
screened? Does their support of you
sometimes vary in relation to their
moods or in relation to changes in
your relationship with them?
What do you think and feel
about the ‘effectiveness’ of
Colonoscopy? How well do you
feel it can accurately tell whether
you or anyone else has colorectal
cancer or growths called polyps
that can develop into colorectal
cancer?
How do you see how your
personal intentions influence
your attitudes and actions as far
as colorectal screening is
concerned? How have you
thought about either FOBT or
Flexible Sigmoidoscopy or
colonoscopy that has influenced
your decision-making or your
intentions to ‘get screened’?
Patient’s experience of gender – differences and specificities in
CRC screening
From what you understand, do
you feel there are male – female
differences in approaching FOBT
screening?
What do you feel are special (male
or female, vary according to the
gender opposite to that of the
interviewee) issues in approaching
Flexible Sigmoidoscopy screening?
Table 1 Semi-structured interview schedule (Continued)
What do you feel are special (male
or female, vary according to
gender of interviewee) issues in
approaching FOBT screening?
What do you feel are common
issues (for males and females) in
approaching Flexible
Sigmoidoscopy screening?
What do you feel are special (male
or female, vary according to the
gender opposite to that of the
interviewee) issues in approaching
FOBT?
Are there any additional points
that we have not covered as far as
gender differences are concerned,
in approaching Flexible
Sigmoidoscopy screening?
What do you feel are common
issues (for males and females) in
approaching FOBT?
From what you understand, do
feel there are male – female
differences in approaching
Colonoscopy screening?
Are there any additional points
that we have not covered as far as
gender differences are concerned,
in approaching FOBT?
What do you feel are special (male
or female, vary according to
gender of interviewee) issues in
approaching Colonoscopy
screening?
From what you understand, do
feel there are male – female
differences in approaching Flexible
Sigmoidoscopy screening?
What do you feel are special (male
or female, vary according to the
gender opposite to that of the
interviewee) issues in approaching
Colonoscopy screening?
What do you feel are special (male
or female, vary according to
gender of interviewee) issues in
approaching Flexible
Sigmoidoscopy screening?
What do you feel are common
issues (for males and females) in
approaching Colonoscopy
screening?
Are there any additional points that
we have not covered as far as
gender differences are concerned, in
approaching Colonoscopy screening?
Patient’s experience of pain and anxiety reponses to CRC screening
How likely do you feel you are to
experience pain and discomfort in
association with getting an FOBT
screening?
How likely are you to face true
dangers in relation to Flexible
Sigmoidoscopy?
How likely do you feel you are to
experience anxieties in relation to
an FOBT screening?
How much do you feel these
experiences of pain, discomfort,
anxiety and/or danger will affect
your decision to get Flexible
Sigmoidoscopy in the future?
How likely are you to face true
dangers in relation to FOBT
screening?
How likely do you feel you are to
experience pain and discomfort in
association with colonoscopy? Why
do you feel the way you do? On
what experience (your experience
or the experiences of others) do you
base your feelings? How likely do
you feel you are to experience
anxieties in relation to colonoscopy?
How much do you feel these
experiences of pain, discomfort,
anxiety and/or danger will affect your
decision to get FOBT in the future?
How likely are you to face true
dangers in relation to
colonoscopy?
How likely do you feel you are to
experience pain and discomfort in
association with Flexible
Sigmoidoscopy?
How much do you feel these
experiences of pain, discomfort,
anxiety and/or danger will affect
your decision to get a
colonoscopy in the future?
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screening). This staging schema, which derives from
the Precaution Adoption Process Model, has been
used to characterize persons eligible for CRCS according
to their attitudinal proximity to action [85]. As no par-
ticipants demonstrated Stage 3 (aware but decided
against), the remaining stages were clustered, for reporting
purposes, into unaware (Stage 1), undecided (Stage 2 and
Stage 4) and decided to do (Stage 5) (see Table 2 below).
Interviews were often undertaken in two sessions, when
respondents indicated needs to meet other schedule de-
mands or reported levels of fatigue that impeded re-
sponses. The mean interview time was 1.8 hours with a
range of 0.56 hours to 2.5 hours.
Care was taken to assure that participants could take
the time needed to carefully consider all response op-
tions before describing experiences. All interviews were
undertaken in English. Of the 81 interviews undertaken,
68 were divided into two or more sessions.
Ethics
Approval was obtained from the Research and Ethics Board
at the University Health Network in Toronto, Ontario.
Data analysis
The demographic characteristics of the interview partici-
pants and their screening stages were tabulated (see
Table 1). All interviews were audio-recorded and tran-
scribed verbatim. The constant comparative method was
used to identify key themes representing attitudes and
preferences that differentiated male–female participants,
with the coding of each interview’s content to identify all
phrases, key words, and expressed concepts. NVivo
8 qualitative analysis software [86] aided coding the
comparisons between expressed concepts identified by par-
ticipants. The constant comparative method is used to
denote a grounded-theory approach that analyzes interview
phenomena from the ground-up, focusing on themes that
emerge directly from data review, while minimizing the
interpretative biases of investigators vulnerable to
pre-existing theoretical orientations.
The transcripts of male and female participants were
coded together, and then codes and themes were com-
pared with respect to gender. Two unblinded team
members coded all transcripts, with periodic discussions
between coders and the principal investigator used to
mediate discrepancies and derive final codes. Two indi-
viduals (one coder and one-non-coder) identified com-
mon themes in the data. Finally, two investigators
reviewed the common themes and identified those
most representative of the gender differences ob-
served. These selections were then reviewed by all in-
vestigators and, n some cases, the descriptive terms
for theme identifiers were revised.
Table 1 Semi-structured interview schedule (Continued)
How likely do you feel you are to
experience anxieties in relation to
Flexible Sigmoidoscopy?
Are there any further experiences
you have had or expect to have
with respect to pain and anxiety in
relation to any form of colorectal
cancer screening that you have
not talked about?
Patient’s experience of personal decision-making in CRC screening
How do you go about making
decisions to undergo or not
undergo FOBT screening?
What about the emotions that you
find you experience when you are
engaged in decision-making about
Flexible Sigmoidoscopy screening?
Can you describe them and how
they affect you?
How do you go about thinking
through your decision?
If you find yourself putting off or
delaying Flexible Sigmoidoscopy
screening, what is that experience
like for you?
What about the emotions you find
you experience when you are
engaged in decision-making about
FOBT screening? Can you describe
them and how they affect you?
How do you go about making
decisions to undergo or not
undergo Colonoscopy screening?
If you find yourself putting off or
delaying FOBT screening, or
thinking about FOBT screening,
what is that experience like for
you?
How do you go about thinking
through your decision?
How do you go about making
decisions to undergo or not
undergo Flexible Sigmoidoscopy
screening?
What about the emotions that you
find you experience when you are
engaged in decision-making about
Colonoscopy screening? Can you
describe them and how they affect
you?
How do you go about thinking
through your decision?
If you find yourself putting off or
delaying Colonoscopy screening,
what is that experience like for
you?
Patient’s experience of personal decision-making in other health
and screening behaviours
How do you go about making
decisions to engage or to not
engage in other health enhancing
or health screening activities?
How do other screening or health
enhancing activities influence your
approach to FOBT screening?
How do you go about thinking
through your decisions to engage
or to not engage in other health
enhancing or health screening
activities?
How do other screening or health
enhancing activities influence your
approach to Flexible
Sigmoidoscopy screening?
What about the emotions that you
find are involved when you are
engaged in decision-making about
other health enhancing or health
screening activities? Can you
describe them and how they affect
you?
How do other screening or health
enhancing activities influence your
approach to Colonoscopy
screening?
If you find yourself putting off or
delaying other health enhancing or
health screening activities, what is
that experience like for you?
Are there any points about other
screening or health enhancing
activities influence your approach
to FOBT or Flexible Sigmoidoscopy
or Colonoscopy screening?
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Results
As seen in Table 1, 49 females and 32 males of screen-
ing eligible age were interviewed about each screening
modality and staged re: readiness-to-screen. A higher
percentage of males were unaware of each modality at
the start of interviews, although a higher percentage of
females were aware but undecided. Nearly equal per-
centages of males and females had already decided to
do FOBT, although appreciably higher proportions of
females had decided to do flexible sigmoidoscopy or
colonoscopy. Staging differences were minimal in
males for all three modalities, while females appeared
to favour both forms of endoscopy over FOBT in their
readiness-to-screen.
Dominant obstructive-cognitive themes - females
Bodily intrusion
Subsumed under this first theme were oral and rectal sub-
themes, related primarily to colonoscopy and flexible sig-
moidoscopy, and to a lesser degree, FOBT. The most
notable references were to the oral ingestion of laxa-
tive mixture, perceived as directly intrusive as the ac-
tual endoscopic procedure. While the intrusion of
scoping was perceived to be buffered by tranquilizing
medication, laxative ingestion was seen as not buffered
and as resulting in diarrhoea, gastric distress and nu-
merous bathroom visits. In terms of scoping intrusion,
most participants had difficulty imagining the level of
pain relief that rendered an endoscopic procedure
relatively painless. FOBT, in contrast, was seen as
indirectly intrusive, given its potential unsanitariness
and the messiness of managing fecal matter, resulting
in exposures to pathogens no less intrusive because
they originated in one’s own body.
“The purging aspect of it (ingestion of laxative
mixture)… you’re the best friend of the toilet …a
24 hour process…”
(referring to colonoscopy)
“…she said it was too painful …couldn’t stand it…. it
was hell … every time…I imagine she wasn’t put
totally out…”
(referring to colonoscopy)
“…there’s so much discomfort and so much problems,
that it should done in a hospital, not…a doctor’s
office….it would be…. Intimidating…”
(referring to colonoscopy)
Table 2 Subject demographics and staging
Females Males
N = 49 N = 32
Age: 51 – 84 years (range) Age: 50 – 77 years (range)
Age: 63.7 years (mean) Age: 65.2 years (mean)
Education: Education:
< High school: 26.5% < High school: 29.5%
Completed high school: 29.3% Completed high school: 27.2%
Completed some college/University: 23.2% Completed some college/university: 24.3%
Completed college/university: 21.0% Completed college/university: 19.0%
Screening1 staging Females Females Females Screening
staging
Males Males Males
FOBT Flex Sig Colonoscopy FOBT Flex Sig Colonoscopy
Unaware 8.1% 8.1% 6.1% Unaware 31.2% 34.4% 34.4%
Undecided 58.2% 44.9% 51% Undecided 34.4% 31.2% 28.1%
Decided to do 34.7% 47% 42.9% Decided to do 34.4% 34.4% 37.5%
Five interview domains









Experience of gender differences in
CRCS
1 As no participants demonstrated Stage 3 (aware but decided against), the remaining stages were clustered, for reporting purposes, into unaware (Stage 1),
undecided (Stage 2 and Stage 4) and decided to do (Stage 5).
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“…you have to drink a terrible amount of soapy stuff
… so you throw it up… then you …try to get the rest…
down… it’s the preparation…
(referring to colonoscopy)
“…just unsanitary….if … not done properly…you’d
be contaminating things….right? …just unpleasant.”
(referring to FOBT)
“…it sounds gross. It isn’t anything I would ever choose
to do….”
(referring to FOBT)
“…not something I’d like to do…I’m put off by it…”
(referring to FOBT)
Perforation anxiety
Separate concerns were verbalized about perforation.
Women, undisturbed by the intrusiveness issues described
above, expressed anxieties specific to perforation injury.
Minimal distinction was made between colonoscopy and
flexible sigmoidoscopy
“… somebody could…rip your colon or you could get
an infection or something else … you wouldn’t run the
risk of that.”
(referring to colonoscopy)
“… it sounds like it could really hurt. That’s… pretty
serious…when you have … an anaesthetic….something
…. to really consider.
(referring to colonoscopy)




While both males and females identified embarrassment,
there was a more personalized and intense expression of
embarrassment in relation to medical professionals by
females.
“…I’ll just….wear a mask, or paper bag over my head
so he doesn’t recognize me…”
(referring to flexible sigmoidoscopy)
“Of course, the ‘con’ would be embarrassment. I can
see a lot of people …shying away …. because it’s such a
personal thing. Once you have a baby though, I mean
‘hello’ (embarrassment is no longer the obstacle)”
“..I really don’t think …most doctors like doing a rectal
examination. And I don’t blame them.”
“..I’ll go to the dentist and have him look down your
throat…the other end… that’s very private…”
(referring to flexible sigmoidoscopy and colonoscopy)
Dominant obstructive themes - males:
Avoidant procrastination with underlying fatalism:
While few male respondents with regular family doctors
challenged their physician’s knowledge or intent in pro-
moting screening, resistance frequently took the form of
blunting and procrastinating the task of obtaining screen-
ing. This was sometimes associated with a vague but per-
sistent notion of being fated for untreatable cancer.
“The advantage of not getting screened…. is to keep
your head in the clouds.”
“What you don’t know, doesn’t hurt you….”
“I’ll call it the fear factor… do I really want to know
that there’s something wrong?”
“I have this terrible thing (idea) that … it’ll kill you
anyway….it’ll get you in the end… so I’d rather not [get
screened] now and live my life the way I do…”
“My physician is right in suggesting it….but I keep
putting it off…” (referring to colonoscopy)
“I think that men …avoid it (colorectal screening)
more… because men don’t like to do …health-related
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things….I think men are, what’s the word I’m
looking for… lazy when it comes to health issues…
they believe… it’s never going to happen to them
until it’s too late (referring to colorectal screening,
generally)
Q. ….if you find yourself delaying health enhancing
behaviours or health screening, what is the experience
like?
A: “Just being lazy I guess….you know, not feeling it is
that important….lazy procrastination…” (referring to
colorectal screening, generally)
Unnecessary health care
Males, particularly those who did not maintain regular
physician contact, saw CRC screening as an unnecessary
component of health care. They tended to see non-
symptomatic illness or illness risk as unworthy of atten-
tion. Only illnesses with disabling symptoms were seen
as necessitating action. While several male respondents
saw cancer and CRC, particularly, as frightening dis-
eases, they did not sustain the idea that screening could
reduce or prevent CRC impact.
Q. And what would you see as major barriers in
obtaining enough knowledge (about CRC screening)?
A. “Lack of interest…if I go read everything on
everything, hell, I’d be very busy. So, basically, you
know, if you don’t have any kind of symptoms, I’m not
going to pursue it….”
Q. What would influence you to get CRC screening?
A. Probably symptoms…I think.
(Referring to colorectal screening, generally)
“…you know unless you absolutely feel …there was
something wrong and it should be checked out, I would
be highly reluctant to go through it…”
(Referring to flexible sigmoidoscopy and colonoscopy)
Uncomfortable vulnerability
Males also indicated discomfort with the exposure of
CRC screening, but more frequently mentioned the ‘pos-
ition of vulnerability’ in screening, rather than being
directly embarrassed in front of a specific health profes-
sional. In contrast to the personalized embarrassment of
females, males seem to object to being in a vulnerable
role position.
“A lot of the guys I know that have it done, they won’t
say anything about it…. the females, they talk about
it….there’s humility on the female side…females are
smarter when it comes to health… because they don’t
let their pride or sense of invasion affect them, whereas
males do…it’s macho vs. humility.”
“There’s something about that area for men… it’s very
vulnerable….putting yourself in that position (when
being screened)…”
(Referring to colonoscopy)
“I think males would be more afraid of the body
invasion than a female….because [of the] super-macho
image whereas women do not have that super-macho
image. They have the feeling of, if I’m sick, I want it
fixed, whereas for a man, it’s ‘Hey, I'm fine.’
(Referring to colorectal screening generally)
Discussion
The study focused on better understanding the attitu-
dinal obstructions identified by respondents re: CRCS
uptake. We specifically focused on gender divergent
obstructions manifested in 4 decision-making stages,
applied to 3 CRC screening modalities (FOBT, flexible
sigmoidoscopy, and colonoscopy). We recruited indivi-
duals at: Stage 1 (never heard of the screening modality);
Stage 2 (aware but not currently considering screening);
Stage 4 (aware but undecided); and Stage 5 (decided to
undergo screening).
The conceptual framework was comprehensive and its
implementation required adjustments guided by three
observations: 1) the great majority of respondents did
not articulate as many differences as assumed obser-
vable; 2) respondents tended to adopt similar attitudes
towards flexible sigmoidoscopy and colonoscopy; 3)
interviewees were rarely in a divergent stage re: one
modality (e.g. colonoscopy) vs. another (e.g. FOBT)
(See Table 1).
The observation that participants, randomly contacted
according by RDD, demonstrated attitudes less
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differentiated than expected, may reflect their true sta-
tus, given the limits of cognitive nuance on selected
topics. Some potential differentiation might have been
diminished by socially desirable responding. Participants
viewed the research as focused on CRC screening pro-
motion and, at times, seemed reluctant to express re-
sponses indicating negative attitudes and rejections of
CRC screening.
The gender differences observed were neither closely
tied to screening stage nor modality. Women, as predict-
able from previous findings, reported more consistent
physician relationships and appeared more knowledgeable
about CRC screening, and better able to articulate views
on screening and screening decisions [21,24,87-90]. Men
reported less consistent physician relationships, were less
knowledgeable and often kept decision-making processes
vague and emotionally distanced (i.e. at ‘arm’s length’).
Male-health researchers have speculated that masculine-
specific values, constructed during male-to-male social in-
teractions, significantly reduce male health [23,28,29,91-98].
Some hypothesize traditional masculine roles as ‘health
hazards’ [94] based on observations that redundant tenden-
cies towards stoicism and emotional suppression, transmit-
ted during masculine-role socialization, are particularly
influential in illness and health-related behaviours[93].
Adherence to other masculine role characteristics, like
excessive self-reliance and dominance, further impede ap-
propriate health service accessing [21,87,88,92,94,98,99].
The specific kind of vague processing observed in
male participants aligns with the blunting construct
where anxiety-provoking situations are distanced emo-
tionally and processed ambiguously, with fragmentation
of content and timing [100-103]. Rather than acknow-
ledge anxiety and the need to decide, men blunt by
distancing anxiety-provoking issues, denying their pos-
sible importance and ambiguously referring to timelines
for effective action. The blunting construct overlaps with
the construct of alexithymia, which defines a more general
deficiency in understanding, processing, and describing
emotions [104-107]. Males have a higher prevalence of
alexithymia (than females) and, when combined with
typical socialization patterns, alexythymic-factors can con-
tribute to a greater tendency towards poor screening health
practices [104,107,108].
According to both blunting and alexythymic perspectives,
when emotions related to decision-making remain ambigu-
ous, actions on one’s behalf (involving confrontation with
risk, distress and anxiety) are impeded [107,109,110].
Avoidant procrastination appeared to be a fundamental
male characteristic with respect to CRCS. In literature on
male socialization, adherence to a ‘stoic’ role impedes
disease prevention, as anxiety (about potential disease) is
often a motivational factor in protective actions [111,112].
While few males expressed a rejection of CRC
screening, males, generally, were less expressively
favourable to screening than females. When they dem-
onstrated favourable attitudes, they often saw themselves
as simply adhering to physician directions.
Past female-specific CRCS research has indicated aver-
sion (when compared to men) to endoscopic screening
(internal scoping in flexible sigmoidoscopy or colonos-
copy) and FOBT (fecal sampling without internal scop-
ing) [35-45]. Comparatively speaking, women were
observed to more frequently arrive at definite screening
decisions, based on protecting personal health, or a delay
because procedures were perceived too distressing. Men,
in contrast, were reluctant to express outright screening
rejections, instead vaguely describing themselves as ‘in the
process of ’ decision-making and action.
The impeding female attitudes were related to high
levels of distress over the physically intrusive, anxiety
provoking aspects of CRCS. Anxiety-sensitivity is an
applicable construct within current psychological litera-
ture, describing a state where problems are avoided
because of fears of anxiety-related sensations, based on
cognitions about harmful anxiety effects [113-120].
When impeded by anxiety-sensitivity, people hyper-react
to immediate stress, feeling stressors do more harm than
the good derived from stress-mastery. When gender dif-
ferences have been tested regarding anxiety-sensitivity,
females demonstrate a higher prevalence, with respect to
the global construct and tend to score high specifically,
on the physical concerns subscale that measures poten-
tial physical harm related to anxiety experiences [121].
This describes the state of female participants who
rejected screening, not solely because of intrusive-
ness, perforation fears or embarrassment, but because
the associated anxiety-related distress seemed too
powerful to even attempt mastery. While lower level
anxieties (i.e. worry) may be conducive to screening
adherence, as indicated in a recent study on the facilitating
effects of worry in breast screening, levels perceived by
females as extreme appear to impede screening [122].
Women who have not had CRCS-related endoscopy fre-
quently state as reasons the fear of pain, the fear of positive
results, embarrassment, inconvenience, expense and the
absence of physician recommendation [8,19,42,123,124].
References to pain are better understood in light of an
established finding that females regularly report more pain/
discomfort with endoscopy (than men) linked to anatom-
ical differences, although this finding does not account for
sedation effects which may attenuate such differences [40].
Additional factors that appear contributive to female en-
doscopy rejection revolve around embarrassment. Many
females prefer female endoscopists [41,43-45,125] and
some investigators suggest the availability of more female
endoscopists would yield higher screening rates, supported
by evidence that women who prefer female endoscopists
Ritvo et al. BMC Public Health 2013, 13:500 Page 9 of 14
http://www.biomedcentral.com/1471-2458/13/500
are less likely to screen [125]. This preference could be
addressed by medical schools and residency programs offer-
ing fellowships, salary incentives, or other recruitment
motivators for female physicians to receive specialty train-
ing in gastroenterology.
In terms of CRCS awareness, women have the advan-
tage of more exposure to cancer screening than men,
given the recommendations of annual/bi-annual cervical
screening (Pap testing) and breast screening (annual/bian-
nual mammography) [126,127]. Existing data supported
the facilitative character of these cancer screening modal-
ities as several studies indicate women who participate in
breast cancer screening are more likely to participate in
CRCS [43,126,128-130].
In applying these findings to screening promotion, the
data suggest males should be supported in taking defini-
tive ‘stands’ on screening, given tendencies to ambigu-
ously procrastinate. Tailored promotion may already
perform this function (by engaging individuals in sys-
tematic decision-making). But the injunction to ‘screen
now, not later’ can additionally counteract tendencies to
delay and render ambiguous screening timelines. On the
other hand, from responses observed, males seem to re-
quire a concerted effort aimed at alerting them to the
need for disease prevention practices altogether. They
seem mired in thinking that only symptomatic and dis-
abling medical problems require care. If this finding is
accurate, a deliberate effort to change these fundamental
attitudes in support of preventive care is required. For
females, their readily expressed anxieties and anxiety-
sensitivity could be counteracted by injunctions to focus
on the relatively limited interval of distress involved
(‘just a few hours could save your life’). With the higher
proportions of breast screening adherence, reference
could be made to similarly overcoming CRCS anxieties
(‘if your breasts are screened, why not your colon?).
Other themes worth emphasizing in counteracting
female obstructive cognitions are the very low risks
associated with colonoscopy, especially when compared
to the sizeable associated reductions in CRC risks. This
theme can be amplified by referring to the extensive
training of colonoscopists and the fact that variably sized
colonoscopes can overcome the differences associated
with female anatomical factors. In terms of FOBT, em-
phasis on the specific design features of kits that
emphasize cleanliness and prevention of contamination
are important. Once again, statistics verifying that these
features effectively reduce risks of infection would be
further reassuring.
Fatalism, in our data, appears an obstructing attitudinal
factor in CRCS in males, confirming existing data
suggesting fatalism is an important negative factor in can-
cer screening in males and females. Current literature
suggests elderly individuals, members of ethnic minorities,
and individuals from lower socioeconomic backgrounds
are particularly susceptible to fatalistic perspectives that
prevent or retard cancer-prevention. As our data accented
fatalism in males, it’s notable that other studies have also
detected a relatively high prevalence of fatalism in males
that impedes health preventive and precautionary behav-
iours [131]. The precision of measurement of fatalistic
attitudes has been aided by the development and psycho-
metric validation of instruments like the Powe Fatalism
Inventory [132] and further study with more precise inves-
tigation is warranted. From our perspective, fatalism could
be a factor that influences men to procrastinate and
render ambiguous screening schedules and activities. On
the other hand, according to the theory of cognitive
dissonance, the behavioural delays of screening might
reciprocally contribute to the attitude that screening is
ineffective, in rationalizing the lack of attentiveness and
precaution manifested behaviourally.
In terms of study limitations, the original conceptual
framework motivated a plan apportioning 15 partici-
pants per gender and screening stage for a total of 120
interviewees (60 males and 60 females). We were only
able to recruit and consent about two-thirds of the
sample target (N = 81) and were especially hampered by
the difficulty of recruiting males. In terms of the
obtained sample, we acknowledge that a mean age of
63.7 years (for females) and 65.2 years (for males) may
appear to indicate too much emphasis on the more
senior decades of CRC screening-eligibility, considering
the need for attention devoted to people in their first
decade of screening eligibility. The skew in our data was
related to being specifically required to not enact an
upper limit age by the Canadian Institute for Health
Research and can be considered a study limitation. This
sampling limitation, however, relates to the concept of
saturation in qualitative research which is defined by the
threshold reached in data collection when no new infor-
mation is identified on a specific topic, within a defined
subject group. When saturation is reached, additional
interviews only yield redundant data rather than novel
findings. One controversy regarding saturation involves
how many additional participants should be interviewed
to confirm no additional information is forthcoming. For
example, after concluding 5 interviews that indicate satu-
ration has been reached, a 6th interview might yield novel
data. While the subsamples of interviewees (32 males and
49 females) seemed sufficient to achieve saturation, and
saturation was observed in the overall gender-specific
samples, the participants recruited per screening stage and
gender were typically less than N = 15 (the number of
interviews often associated with saturation). It is possible
then that had we recruited greater numbers of partici-
pants, saturation would have been further confirmed, in
terms of gender per screening stage. This level of precision
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awaits future studies that likely will confront the difficulties
we encountered. The response rate of contacted individuals
through RDD was low (< 2%) meaning that 100 calls yield
2 eligible, consented participants and a total greater than
4000 calls were necessary.
Conclusion
Marked differences were observed in obstructive CRCS
cognitions per gender. While females articulated reserva-
tions about CRCS-associated distress, males suppressed
negative views but ambiguously related to the task of com-
pleting screening. Their procrastination sometimes masked
a deeper fatalism about cancer disease and disbelief in the
preventive-protective elements of screening. While both
genders cited embarrassment as an obstacle, female percep-
tions were personalized (identifying a health provider) while
males more generally referred to vulnerability without
envisioning a specific person encountered.
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